Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05473793

Impact of a Dried Vegetable on Bowel Function and Gut Microbiota

A randomized, placebo-controlled, parallel, double-blind trial with three intervention arms and a period of four intervention-weeks that assesses the intake of different dosages of a complex fiber product on bowel function via microbiota changes in subjects that are unsatisfied with their current bowel function.

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Wageningen University & Research, Division of Human Nutrition & Health

Wageningen, Gelderland, 6708 WE, Netherlands

Location status: Recruiting

Location contact

Edith JM Feskens, Prof. dr.

PRINCIPAL_INVESTIGATOR

Marie-Luise Puhlmann, MSc

CONTACT

[email protected]

+31 6 38 03 11 29

Sofie CC van der Zalm, MSc

CONTACT

[email protected]

+31 6 18 41 71 62

About this study

Background: Bowel function issues can have a substantial effect on quality of life. Additional fiber intake might modulate bowel function and gut microbiota, thereby increasing stool frequency and consistency. This could improve defecation ease, feeling of incomplete bowel emptying and bowel function satisfaction. We hypothesize that a dried vegetable, that is naturally high in fiber within plant cells could improve bowel function in subjects with bowel function issues.

Objective: The main objective of the study is to assess whether a dried multifiber vegetable improves bowel function assessed by stool frequency, consistency, defecation ease, feeling of incomplete bowel emptying and satisfaction. Secondary objectives are to assess whether these effects are dose-dependent and associated with the modulation of the gut microbiota and activity. Furthermore, the adaption of bowel function and adaptation of the gut microbiota and activity over time will be analyzed.

Study design: A parallel, randomized, double-blind, placebo-controlled trial of four weeks with one placebo control and three intervention arms that differ in intervention product dose.

Study population: Healthy human volunteers, 20 - 80y old, with bowel function issues reflected in low stool frequency/consistency, difficulty to defecate, and dissatisfaction with their current bowel function.

Intervention: A vegetable product consisting of dried chicory root cubes containing 85% dietary fiber is added to the daily diet. The intervention product is consumed twice daily for four weeks with a maximum dose of 15 g/day. The control (placebo) consists of easily digestible rice puff particles and is consumed in the same manner as the intervention.

Main study parameters/endpoints: Main study outcome are endpoint (week 4) differences from baseline between the highest dose (15 g/day) of the treatment intervention and placebo in bowel function assessed by changes in stool frequency, stool consistency, ease of defecation, incomplete feeling of bowel emptying and bowel function satisfaction. Secondary endpoints are gut microbiota composition and differences in bowel function, quality of life and constipation symptoms assessment between all doses and placebo. Finally, changes over time in gut microbiota and bowel function will be assessed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 20 - 80 years old
  • Unsatisfied with bowel functions (self-reported), rated on a visual analogue scale (VAS, 0-10) as less than 6
  • Four or less bowel movements per week (low stool frequency) and/or
  • Hard, lumpy or solid stools (Bristol stool form 1-4) during 90% of bowel movements (hard to solid consistency)
  • Able to read and understand Dutch or English

Exclusion criteria

  • Having a history of medical or surgical events that may significantly affect the study outcome: e.g., IBS or IBD patients and subjects with medically diagnosed constipation (i.e., constipation related to anatomic, medication-related, or readily identifiable physiological causes.)
  • Less than one bowel movement per week during the screening
  • Medical drug use:
  • Antibiotic use within 3 months of the study screenings day
  • Chronic use of antacids and PPI's
  • Use of laxatives during the screening
  • Chronic use of blood glucose lowering medication
  • Consumption of supplements containing fibres (other than laxatives), pro-/ post-/ synbiotics 1 month before the screening
  • Not willing to provide faecal samples
  • Unable to comply with proper study procedures
  • For women of childbearing age: current or planned pregnancy, lactation
  • Known allergic reactions to plants from the Asteraceae (Compositae) family (e.g., lettuce, daisies, sunflowers, artichokes, sage, tarragon, chamomile, chicory etc.)
  • Reported unexplained weight loss or weight gain of greater than 5 kg in the month prior to pre-study screening
  • Reported slimming or medically prescribed diet
  • Reported macrobiotic lifestyle
  • Personnel the Division of Human Nutrition & Health or the Laboratory of Microbiology
  • Current participation in other medical scientific research
  • Not having a general practitioner
  • Not willing to be informed about accidental discoveries in relation to the subjects health

Treatment and study plan

Dried chicory root particles

Dietary Supplement

The intervention product consists of chicory root that have been sliced and dried and are provided in the form of particles (~3mm).

Other names: brand name: WholeFiber™

Placebo

Other

The control arm receives a placebo consisting of rice puff particles.

Other names: Rice puff particles

Primary outcomes

  1. Bowel function (differences highest dose vs placebo) - bowel function satisfaction

    Time frame: Change after the intervention of 4 weeks

    Bowel function satisfaction is rated on a five-point scale (from "0-not at all" to "4-extremely").

  2. Bowel function (differences highest dose vs placebo) - ease of defecation

    Time frame: Change after the intervention of 4 weeks

    Ease of defecation is rated on a five-point scale (from "0-not at all" to "4-extremely").

  3. Bowel function (differences highest dose vs placebo) - feeling of incomplete bowel emptying

    Time frame: Change after the intervention of 4 weeks

    Feeling of incomplete bowel emptying is rated on a five-point scale (from "0-not at all" to "4-extremely").

  4. Bowel function (differences highest dose vs placebo) - stool consistency

    Time frame: Change after the intervention of 4 weeks

    Stool consistency is measured using the Bristol Stool Form Scale (7-point scale from 1=hard to 7=diarrhea).

  5. Bowel function (differences highest dose vs placebo) - stool frequency

    Time frame: Change after the intervention of 4 weeks

    Stool frequency is measured by counting number of bowel movements per week.

Secondary outcomes

  1. Fecal gut microbiota (between dose differences)

    Time frame: Change after the intervention of 4 weeks

    Measured in fecal samples using DNA sequencing. Compared between different fiber dosages and placebo.

  2. Fecal gut microbiota activity (between dose differences)

    Time frame: Change after the intervention of 4 weeks

    Fecal gut microbiota activity is determined by measuring microbial metabolites in fecal samples among which fermentation products (short-chain fatty acids) using HPLC. Compared between different fiber dosages and placebo.

  3. Quality of Life (between dose differences)

    Time frame: Change after the intervention of 4 weeks

    Quality of life is measured using the questionnaire Patient Assessment of Constipation - Quality of Life. Compared between different fiber dosages and placebo.

  4. Constipation-related symptoms (between dose differences)

    Time frame: Change after the intervention of 4 weeks

    Constipation symptoms is measured using the questionnaire Patient Assessment of Constipation - Symptoms. Compared between different fiber dosages and placebo.

  5. Bowel function (between dose differences) - bowel function satisfaction

    Time frame: Change after the intervention of 4 weeks

    Bowel function satisfaction is rated on a five-point scale (from "0-not at all" to "4-extremely").

    Compared between different fiber dosages and placebo.

  6. Bowel function (between dose differences) - ease of defecation

    Time frame: Change after the intervention of 4 weeks

    Ease of defecation is rated on a five-point scale (from "0-not at all" to "4-extremely"). Compared between different fiber dosages and placebo.

  7. Bowel function (between dose differences) - feeling of incomplete bowel emptying

    Time frame: Change after the intervention of 4 weeks

    Feeling of incomplete bowel emptying is rated on a five-point scale (from "0-not at all" to "4-extremely"). Compared between different fiber dosages and placebo.

  8. Bowel function (between dose differences) - stool consistency

    Time frame: Change after the intervention of 4 weeks

    Stool consistency is measured using the Bristol Stool Form Scale (7-point scale from 1=hard to 7=diarrhea). Compared between different fiber dosages and placebo.

  9. Bowel function (between dose differences) - stool frequency

    Time frame: Change after the intervention of 4 weeks

    Stool frequency is measured by counting number of bowel movements per week. Compared between different fiber dosages and placebo.

Other outcomes

  1. Bowel function (weekly changes) - bowel function satisfaction

    Time frame: Weekly development for a period of 4 weeks

    Bowel function satisfaction is rated on a five-point scale (from "0-not at all" to "4-extremely"). Compared between different fiber dosages and placebo.

  2. Bowel function (weekly changes) - ease of defecation

    Time frame: Weekly development for a period of 4 weeks

    Ease of defecation is rated on a five-point scale (from "0-not at all" to "4-extremely").

  3. Bowel function (weekly changes) - feeling of incomplete bowel emptying

    Time frame: Weekly development for a period of 4 weeks

    Feeling of incomplete bowel emptying is rated on a five-point scale (from "0-not at all" to "4-extremely").

  4. Bowel function (weekly changes) - stool consistency

    Time frame: Weekly development for a period of 4 weeks

    Stool consistency is measured using the Bristol Stool Form Scale (7-point scale from 1=hard to 7=diarrhea).

  5. Bowel function (weekly changes) - stool frequency

    Time frame: Weekly development for a period of 4 weeks

    Stool frequency is measured by counting number of bowel movements per week.

  6. Fecal gut microbiota (weekly changes)

    Time frame: Weekly development for a period of 4 weeks

    Measured in fecal samples using DNA sequencing.

  7. Fecal gut microbiota activity (weekly changes)

    Time frame: Weekly development for a period of 4 weeks

    Fecal gut microbiota activity is determined by measuring microbial metabolites in fecal samples among which fermentation products (short-chain fatty acids) using HPLC.

Study contacts

Contact information is provided by the study sponsor or research team.

Edith JM Feskens, Prof. dr

CONTACT

[email protected]

+31317482567

Sofie CC van der Zalm, MSc

CONTACT

[email protected]

+31618417162

Sponsors and collaborators

Lead sponsor

Wageningen University

Other

Collaborators

  • Wageningen University and Research
  • Wageningen University and Research, Division of Human Nutrition & Health
  • Wageningen University and Research, Laboratory of Microbiology
  • WholeFiber BV

Registry information

Official study title

The Impact of a Dried Vegetable on Bowel Function and Gut Microbiota in Subjects With Bowel Function Issues

Acronym: HappYFiber

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Jul 26, 2022
Registry last updated
Feb 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.